IL108367D0 - Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells - Google Patents

Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells

Info

Publication number
IL108367D0
IL108367D0 IL10836794A IL10836794A IL108367D0 IL 108367 D0 IL108367 D0 IL 108367D0 IL 10836794 A IL10836794 A IL 10836794A IL 10836794 A IL10836794 A IL 10836794A IL 108367 D0 IL108367 D0 IL 108367D0
Authority
IL
Israel
Prior art keywords
polynzcleotide
antisense
inhibition
growth factor
cancer cells
Prior art date
Application number
IL10836794A
Original Assignee
Hektoen Inst For Medical Resea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US959693A priority Critical
Application filed by Hektoen Inst For Medical Resea filed Critical Hektoen Inst For Medical Resea
Publication of IL108367D0 publication Critical patent/IL108367D0/en

Links

IL10836794A 1993-01-27 1994-01-18 Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells IL108367D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US959693A true 1993-01-27 1993-01-27

Publications (1)

Publication Number Publication Date
IL108367D0 true IL108367D0 (en) 1994-04-12

Family

ID=21738623

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10836794A IL108367D0 (en) 1993-01-27 1994-01-18 Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells

Country Status (4)

Country Link
US (2) US5610288A (en)
AU (1) AU6097094A (en)
IL (1) IL108367D0 (en)
WO (1) WO1994016738A1 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT281183T (en) 1993-07-30 2004-11-15 Alliance Pharma Stabilized mikrogasblaeschen-compositions for Echografie
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
EP0856052A1 (en) * 1995-09-20 1998-08-05 University of Massachusetts Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US6057156A (en) * 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
JP2005504513A (en) 2001-05-09 2005-02-17 コリクサ コーポレイション Compositions and methods for prostate cancer therapy and diagnosis
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US5914269A (en) 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
US6586661B1 (en) * 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
US7052692B1 (en) 1997-09-02 2006-05-30 Advanced Research & Technology Institute Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
US20030143204A1 (en) * 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
JP2004513615A (en) 2000-06-28 2004-05-13 コリクサ コーポレイション Compositions and methods for the treatment and diagnosis of lung cancer
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO1999063975A2 (en) 1998-06-10 1999-12-16 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A method for stimulating the immune system
AT399541T (en) * 1998-08-18 2008-07-15 Univ California Epidermal growth factor receptor antagonists for the treatment greatly increased mucus secretion in the lungs
US7094533B1 (en) * 1999-01-21 2006-08-22 Board Of Regents Of The University Of Nebraska Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
JP2002538820A (en) * 1999-03-17 2002-11-19 ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション Preparation and use of cDNA libraries that are not cloned micro clones
DE19926216A1 (en) * 1999-06-09 2001-02-22 Metallgesellschaft Ag A process for the preparation of barium sulfate, barium sulfate and barium sulfate using the
US7662793B2 (en) * 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomelekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
WO2002018607A2 (en) * 2000-08-30 2002-03-07 North Carolina State University Transgenic plants containing molecular decoys that alter protein content therein
US6444465B1 (en) * 2000-09-29 2002-09-03 Isis Pharmaceuticals, Inc. Antinsense modulation of Her-1 expression
DE60128149D1 (en) * 2000-11-07 2007-06-06 Univ North Carolina State Putrescin-n-methyltransferasepromotor
JP2004530430A (en) * 2001-06-08 2004-10-07 ベクター、タバコ、リミテッドVector Tobacco Ltd. Changing the concentration of nicotine and nitrosamines in tobacco
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
ES2405405T3 (en) 2001-12-17 2013-05-31 Corixa Corporation Compositions and methods for therapy and diagnosis of inflammatory bowel disease
EP1499188A4 (en) * 2002-04-09 2007-11-14 Vector Tobacco Ltd Tobacco having reduced nicotine and nitrosamines
AU2003300776A1 (en) * 2002-09-09 2004-05-25 Omeros Corporation G protein coupled receptors and uses thereof
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US8722872B2 (en) * 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
EP2216029A3 (en) 2002-10-02 2010-12-22 The University Of British Columbia Oligonucleotides for treatment of prostate and other cancers
PT1625166E (en) 2003-05-12 2015-08-20 Helion Biotech Aps Antibodies to masp-2
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
US20050287668A1 (en) * 2003-11-04 2005-12-29 Cell Therapeutics, Inc. (Cti) RNA interference compositions and screening methods for the identification of novel genes and biological pathways
US7455840B2 (en) * 2003-11-19 2008-11-25 The Scripps Research Institute Compositions and methods to reduce mutagenesis
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
EP2465534B1 (en) 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP2006315017A (en) * 2005-05-11 2006-11-24 Canon Inc Laser beam cutting method, and member to be cut
ES2419106T3 (en) * 2005-12-01 2013-08-19 Pronai Therapeutics, Inc. Amphoteric liposomes Formulation
DK2671954T3 (en) 2006-01-20 2018-08-13 Cell Signaling Technology Inc Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP2450437B1 (en) 2006-04-14 2017-05-17 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
JPWO2008105441A1 (en) * 2007-02-27 2010-06-03 味の素株式会社 Polyamino acid compound having a phosphate anti-resorptive activity and phosphorus absorption inhibitor
US9381209B2 (en) * 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy
BRPI0809244A2 (en) 2007-03-27 2014-09-23 Omeros Corp Methods of treating an abnormal movement, and for identifying an agent that inhibits PDE7 activity.
DK2203558T3 (en) 2007-10-18 2016-06-27 Cell Signaling Technology Inc TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
AU2008340355B2 (en) 2007-12-04 2015-01-22 Tekmira Pharmaceuticals Corporation Targeting lipids
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
CA2721333A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
CA2984026A1 (en) 2008-10-09 2010-04-15 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN105709229A (en) 2008-11-10 2016-06-29 阿尔尼拉姆医药品有限公司 Novel lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
WO2010093928A2 (en) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
US20100285112A1 (en) 2009-05-05 2010-11-11 Tatiana Novobrantseva Methods of delivering oligonucleotides to immune cells
JP5769701B2 (en) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation Lipid composition
EP3431076A1 (en) 2009-06-10 2019-01-23 Arbutus Biopharma Corporation Improved lipid formulation
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
PT2488203T (en) * 2009-10-16 2017-03-10 Univ Leicester Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
NZ610925A (en) 2010-11-08 2015-10-30 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc Pegylated lipids and their use for drug delivery
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3287142A1 (en) 2011-04-08 2018-02-28 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
EP3456317A1 (en) 2011-09-27 2019-03-20 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
EP3336181A1 (en) 2012-04-18 2018-06-20 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
SG11201507211YA (en) * 2013-03-11 2015-10-29 Univ North Carolina Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
AU2014287002A1 (en) 2013-07-11 2016-02-11 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034997A (en) * 1983-05-09 1985-02-22 Jiyosefu Todaro Jiyooji Biologically active polypeptides
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
EP0246753B1 (en) * 1986-04-22 1994-07-13 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
US4999421A (en) * 1988-06-27 1991-03-12 Triton Biosciences Inc. HTLV-I anti-sense RNA and encoded proteins
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5182261A (en) * 1989-07-13 1993-01-26 The Rockefeller University Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides

Also Published As

Publication number Publication date
US5891858A (en) 1999-04-06
US5610288A (en) 1997-03-11
AU6097094A (en) 1994-08-15
WO1994016738A1 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
AU665533B2 (en) Treatment of material
AU663356B2 (en) Surgical implant
GB2328691B (en) Inhibition of microbial growth
AU679165B2 (en) Treatment of inflammation
EP0451611A3 (en) Human hematopoietic stem cell
HU901359D0 (en) Enossalic onedental implant and counter-implement for using of this implant
HK1012489A1 (en) Composition for revitalizing scar tissue
PL332851A1 (en) Novel homoloques of fibroblast growth factor
AU8320591A (en) Enzymatic treatment of silage
HRP970387A2 (en) Isobutylgaba and its derivatives for the treatment of pain
HU9301448D0 (en) Inhibitors of double actioh
AU6418394A (en) Removal of tissue
GB9122318D0 (en) Treatment of elongate members
EP0871494A4 (en) Compositions and methods for treating tumor cells
AU3760295A (en) Treatment of nutrient-rich water
IE891738L (en) Transforming plant tissues
ZA9407799B (en) Inhibition of cytokine production
EP0787142A4 (en) Neurturin and related growth factors
AU1577792A (en) Implantation tissue and treatment and use methods
AU639192B2 (en) Treatment of water
ZA8503949B (en) Implant tissue
AU3943893A (en) Antisense oligonucleotide inhibition of papillomavirus
AU1086597A (en) Reduction of hair growth
AU5093593A (en) Inhibition of tumor metastasis via neutralization of tissue factor function
AU1994792A (en) Targeted delivery of bone growth factors